Method, composition and kit for antigenic binding of norwalk-like viruses

A method for preventing or treating an active Norwalk-Like Virus (NLV) infection in the gastrointestinal (GI) tract of a host, comprising the step of administering orally a fucosyl α1→2 carbohydrate compound to the host, wherein the compound has the binding specificity of the antigenic determinant of a human histo-blood group antigen and competitively binds with a NLV at the determinant binding site of the NLV and wherein the compound inhibits binding of the NLV in vivo to a histo blood group antigen of the host, thereby inhibiting the active infection or preventing infection of the GI tract of the host by the NLV.

Use of a fucosyl α1→2 carbohydrate compound having the binding specificity of the antigenic determinant of a human histo-blood group antigen and that competitively binds with a NLV at the determinant binding site of the NLV, in an effective amount of the compound sufficient to inhibit binding of the NLV in vivo to a histo blood group antigen of a host that has or is susceptible to a NLV infection, which inhibits the active infection or prevents an infection of the host by the NLV, to treat an active infection or to prevent an infection in the gastrointestinal (GI) tract of the host.